Who makes Daptomycin antimicrobial-lock solution?

Daptomycin antimicrobial-lock solution is developed by Clinica Universidad de Navarra, Universidad de Navarra.

What development phase is Daptomycin antimicrobial-lock solution in?

Daptomycin antimicrobial-lock solution is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Clinica Universidad de Navarra, Universidad de Navarra · FDA-approved active Small molecule Quality 2/100

Generic name	Daptomycin antimicrobial-lock solution
Also known as	daptomycin: cubicin 350 mg vial., sodium heparin 1%, 5000 IU/5ml., lactated ringer´s solution 500 ml viaflo.
Sponsor	Clinica Universidad de Navarra, Universidad de Navarra
Modality	Small molecule
Phase	FDA-approved

No approved indications tracked.

No common side effects on file.

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results